AstraZeneca To Pay $11M To Settle Toprol-XL Antitrust Claims

Law360, New York (September 25, 2012, 11:18 PM EDT) -- AstraZeneca Pharmaceuticals LP on Tuesday agreed to pay $11 million to settle claims by a proposed class of indirect purchasers of hypertension drug Toprol-XL that the drugmaker used sham patent litigation to prolong a monopoly on the drug by delaying generic versions.

In a settlement motion filed in Delaware federal court, the plaintiffs sought approval for a settlement class of indirect purchasers of Toprox-XL dating back to May 2005. According to the motion, AstraZeneca denied any wrongdoing but said it wanted to avoid expensive litigation....
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.